Corvus Pharmaceuticals, Inc. (CRVS) Earnings History
Net Loss12 years of earnings data (2014–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Corvus Pharmaceuticals, Inc. (CRVS) Earnings Overview
As of November 9, 2026, Corvus Pharmaceuticals, Inc. (CRVS) reported trailing twelve-month net income of -$64M, reflecting +48.0% year-over-year growth. The company earned $-0.70 per diluted share over the past four quarters.
Looking at the long-term picture, CRVS's historical earnings data spans multiple years. The company achieved its highest annual net income of -$176,000 in fiscal 2014.
Corvus Pharmaceuticals, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including IMVT (-$538M net income), RCUS (-$445M net income, -142.9% margin), TPVG ($22M net income, 69.6% margin), CRVS has comparable earnings metrics. Compare CRVS vs IMVT →
CRVS Earnings vs Peers
Earnings metrics vs comparable public companies
CRVS Historical Earnings Data (2014–2025)
12 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$15M | +75.5% | -$43M | $-0.53 | - | - |
| 2024 | -$62M | -130.5% | -$28M | $-1.02 | - | - |
| 2023 | -$27M | +34.6% | -$23M | $-0.56 | - | - |
| 2022 | -$41M | +4.5% | -$33M | $-0.89 | - | - |
| 2021 | -$43M | -621.3% | -$39M | $-1.03 | - | - |
| 2020 | -$6M | +87.2% | -$44M | $-0.20 | - | - |
| 2019 | -$47M | +0.6% | -$49M | $-1.49 | - | - |
| 2018 | -$47M | +15.7% | -$49M | $-1.71 | - | - |
| 2017 | -$56M | -53.0% | -$57M | $-2.72 | - | - |
| 2016 | -$36M | -16.1% | -$37M | $-2.36 | - | - |
| 2015 | -$31M | -17704.0% | -$14M | $-1.54 | - | - |
| 2014 | $-176,000 | - | $-176,000 | $-1.03 | - | - |
Download Data
Export CRVS earnings history in CSV or JSON format
Free sign-in required to download data
CRVS Chart Terminal
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
Live Breakouts Feed
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
12+ years return with dividends reinvested.
Peer Comparison
Compare growth, multiples, and margins vs sector.
CRVS — Frequently Asked Questions
Quick answers to the most common questions about buying CRVS stock.
What is CRVS earnings per share (EPS)?
CRVS trailing twelve-month (TTM) diluted EPS is $-0.70, reflecting +48.0% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2014 to 2025 is available in the table on this page.
What is Corvus Pharmaceuticals, Inc.'s net income?
Corvus Pharmaceuticals, Inc. (CRVS) trailing twelve-month net income is $-64M as of 2025. Earnings grew +48.0% year-over-year.
Is CRVS profitable?
CRVS is not currently profitable on a TTM basis, reporting a net loss of $-64M. Net margin is N/A. Investors should monitor for a return to profitability.
What is CRVS's earnings growth rate?
CRVS compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2014 to 2025.
What are CRVS's profit margins?
Corvus Pharmaceuticals, Inc. net profit margin is N/A, operating margin is N/A, and gross margin is N/A. Below-average margins reflect competitive or cost pressures. Return on Equity is -32.6%.
Is CRVS growing earnings?
Yes, CRVS earnings are accelerating — EPS growth of +48.0% exceeds the 5-year CAGR of N/A. TTM net income reached $-64M. Earnings momentum is strengthening.
What was CRVS's best earnings year?
Corvus Pharmaceuticals, Inc.'s highest annual net income on record is $-176000.00, achieved in fiscal year 2014. Earnings history on this page spans 2014 to 2025 and includes all annual and quarterly figures.
What were CRVS's earnings last quarter?
CRVS's most recent reported quarter was Q3 2026. Net income was $-20M with diluted EPS of $-0.22. For a full breakdown of all quarters, see the quarterly earnings table on this page.